137 related articles for article (PubMed ID: 29088776)
1. Expression differences of programmed death ligand 1 in de-novo and recurrent glioblastoma multiforme.
Heynckes S; Gaebelein A; Haaker G; Grauvogel J; Franco P; Mader I; Carro MS; Prinz M; Delev D; Schnell O; Heiland DH
Oncotarget; 2017 Sep; 8(43):74170-74177. PubMed ID: 29088776
[TBL] [Abstract][Full Text] [Related]
2. Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme.
Heynckes S; Daka K; Franco P; Gaebelein A; Frenking JH; Doria-Medina R; Mader I; Delev D; Schnell O; Heiland DH
BMC Cancer; 2019 Feb; 19(1):117. PubMed ID: 30709339
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of PD-L1 expression in glioblastoma multiforme.
Heiland DH; Haaker G; Delev D; Mercas B; Masalha W; Heynckes S; Gäbelein A; Pfeifer D; Carro MS; Weyerbrock A; Prinz M; Schnell O
Oncotarget; 2017 Jun; 8(26):42214-42225. PubMed ID: 28178682
[TBL] [Abstract][Full Text] [Related]
4. Temozolomide promotes immune escape of GBM cells via upregulating PD-L1.
Wang S; Yao F; Lu X; Li Q; Su Z; Lee JH; Wang C; Du L
Am J Cancer Res; 2019; 9(6):1161-1171. PubMed ID: 31285949
[TBL] [Abstract][Full Text] [Related]
5. Detection of temozolomide-induced hypermutation and response to PD-1 checkpoint inhibitor in recurrent glioblastoma.
Daniel P; Meehan B; Sabri S; Jamali F; Sarkaria JN; Choi D; Garnier D; Kitange G; Glennon KI; Paccard A; Karamchandani J; Riazalhosseini Y; Rak J; Abdulkarim B
Neurooncol Adv; 2022; 4(1):vdac076. PubMed ID: 35795471
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 expression and prognostic impact in glioblastoma.
Nduom EK; Wei J; Yaghi NK; Huang N; Kong LY; Gabrusiewicz K; Ling X; Zhou S; Ivan C; Chen JQ; Burks JK; Fuller GN; Calin GA; Conrad CA; Creasy C; Ritthipichai K; Radvanyi L; Heimberger AB
Neuro Oncol; 2016 Feb; 18(2):195-205. PubMed ID: 26323609
[TBL] [Abstract][Full Text] [Related]
7. Growth and differentiation factor 15 regulates PD-L1 expression in glioblastoma.
Peng H; Li Z; Fu J; Zhou R
Cancer Manag Res; 2019; 11():2653-2661. PubMed ID: 31114328
[No Abstract] [Full Text] [Related]
8. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
[TBL] [Abstract][Full Text] [Related]
9. Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues.
Majzner RG; Simon JS; Grosso JF; Martinez D; Pawel BR; Santi M; Merchant MS; Geoerger B; Hezam I; Marty V; Vielh P; Daugaard M; Sorensen PH; Mackall CL; Maris JM
Cancer; 2017 Oct; 123(19):3807-3815. PubMed ID: 28608950
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 Expression Correlated with p53 Expression in Pediatric Glioblastoma Multiforme.
Litak J; Grajkowska W; Szumiło J; Krukow P; Maciejewski R; Roliński J; Grochowski C
Brain Sci; 2021 Feb; 11(2):. PubMed ID: 33669639
[TBL] [Abstract][Full Text] [Related]
11. Paliperidone Inhibits Glioblastoma Growth in Mouse Brain Tumor Model and Reduces PD-L1 Expression.
Liu YS; Huang BR; Lin CJ; Shen CK; Lai SW; Chen CW; Lin HJ; Lin CH; Hsieh YC; Lu DY
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503167
[TBL] [Abstract][Full Text] [Related]
12. TLR3 regulates PD-L1 expression in human cytomegalovirus infected glioblastoma.
Qin Z; Zhang L; Xu Y; Zhang X; Fang X; Qian D; Liu X; Liu T; Li L; Yu H; Wang B
Int J Clin Exp Pathol; 2018; 11(11):5318-5326. PubMed ID: 31949612
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint in Glioblastoma: Promising and Challenging.
Huang J; Liu F; Liu Z; Tang H; Wu H; Gong Q; Chen J
Front Pharmacol; 2017; 8():242. PubMed ID: 28536525
[TBL] [Abstract][Full Text] [Related]
14. Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer.
Remon J; Chaput N; Planchard D
Curr Opin Oncol; 2016 Mar; 28(2):122-9. PubMed ID: 26756384
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Perry JR; Bélanger K; Mason WP; Fulton D; Kavan P; Easaw J; Shields C; Kirby S; Macdonald DR; Eisenstat DD; Thiessen B; Forsyth P; Pouliot JF
J Clin Oncol; 2010 Apr; 28(12):2051-7. PubMed ID: 20308655
[TBL] [Abstract][Full Text] [Related]
16. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614
[TBL] [Abstract][Full Text] [Related]
17. Impact of pre-therapy glioblastoma multiforme microenvironment on clinical response to autologous CMV-specific T-cell therapy.
Walker DG; Shakya R; Morrison B; Neller MA; Matthews KK; Nicholls J; Smith C; Khanna R
Clin Transl Immunology; 2019; 8(11):e01088. PubMed ID: 31929892
[TBL] [Abstract][Full Text] [Related]
18. [Expression of Programmed Death Ligand-1 (PD-L1) in Human Acute Leukemia and Its Clinical Significance].
Zhang ZF; Zhang QT; Xin HZ; Gan SL; Ma J; Liu YF; Xie XS; Sun H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Aug; 23(4):930-4. PubMed ID: 26314420
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme.
Groves MD; Puduvalli VK; Hess KR; Jaeckle KA; Peterson P; Yung WK; Levin VA
J Clin Oncol; 2002 Mar; 20(5):1383-8. PubMed ID: 11870183
[TBL] [Abstract][Full Text] [Related]
20. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
